Advances in stem cell mobilization

Blood Reviews

Volumn 28, Issue 1, 2014, Pages 31-40

  Hopman, Rusudan K ^a   DiPersio, John F ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

G CSF; Parathyroid hormone; Plerixafor; SDF 1; Stem cell mobilization

Indexed keywords

5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ALKALINE PHOSPHATASE; BKT 140; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CYCLOPEPTIDE; CYCLOPHOSPHAMIDE; EPIRUBICIN; ETOPOSIDE; GARNOCESTIM; HYPOXIA INDUCIBLE FACTOR; IFOSFAMIDE; NATALIZUMAB; NOX A12; PARATHYROID HORMONE; PLACEBO; PLERIXAFOR; POL 6326; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT STEM CELL FACTOR; SPHINGOSINE 1 PHOSPHATE; STROMAL CELL DERIVED FACTOR 1; T 140; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ALLOGENEIC STEM CELL TRANSPLANTATION; APHERESIS; ARTHRALGIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE PAIN; CD34 SELECTION; CROHN DISEASE; DIARRHEA; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; ERYTHEMA; FATIGUE; FEVER; FLU LIKE SYNDROME; GRAFT VERSUS HOST REACTION; HEADACHE; HEMATOPOIETIC STEM CELL; HLA MATCHING; HUMAN; HYPERTENSION; INJECTION SITE REACTION; LEUKAPHERESIS; MALAISE; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RASH; REVIEW; SINGLE DRUG DOSE; STEM CELL MOBILIZATION; STEM CELL NICHE; UNRELATED DONORS; UNSPECIFIED SIDE EFFECT;

G-CSF; PARATHYROID HORMONE; PLERIXAFOR; SDF-1; STEM CELL MOBILIZATION;

ANIMALS; BONE MARROW; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELLS; HUMANS;

EID: 84895174116     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2014.01.001     Document Type: Article

References (159)

1. Attal M., Harousseau J.L., Stoppa A.M., Sotto J.J., Fuzibet J.G., Rossi J.F., et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996, 335:91-97.
2. Child J.A., Morgan G.J., Davies F.E., Owen R.G., Bell S.E., Hawkins K., et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003, 348:1875-1883.
3. Schmitz N., Pfistner B., Sextro M., Sieber M., Carella A.M., Haenel M., et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002, 359:2065-2071.
4. Philip T., Guglielmi C., Hagenbeek A., Somers R., Van der Lelie H., Bron D., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995, 333:1540-1545.
5. Rohatiner A.Z., Nadler L., Davies A.J., Apostolidis J., Neuberg D., Matthews J., et al. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. J Clin Oncol 2007, 25:2554-2559.
6. Weaver C.H., Hazelton B., Birch R., Palmer P., Allen C., Schwartzberg L., et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative chemotherapy. Blood 1995, 86:3961-3969.
7. Reiffers J., Faberes C., Boiron J.M., Marit G., Foures C., Ferrer A.M., et al. Peripheral blood progenitor cell transplantation in 118 patients with hematological malignancies: analysis of factors affecting the rate of engraftment. J Hematother 1994, 3:185-191.
8. Pulsipher M.A., Chitphakdithai P., Logan B.R., Leitman S.F., Anderlini P., Klein J.P., et al. Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. Blood 2009, 114:2606-2616.
9. Baron F., Maris M.B., Storer B.E., Sandmaier B.M., Panse J.P., Chauncey T.R., et al. High doses of transplanted CD34+ cells are associated with rapid T-cell engraftment and lessened risk of graft rejection, but not more graft-versus-host disease after nonmyeloablative conditioning and unrelated hematopoietic cell transplantation. Leukemia 2005, 19:822-828.
10. Gorin N.C., Labopin M., Boiron J.M., Theorin N., Littlewood T., Slavin S., et al. Results of genoidentical hemopoietic stem cell transplantation with reduced intensity conditioning for acute myelocytic leukemia: higher doses of stem cells infused benefit patients receiving transplants in second remission or beyond-the Acute Leukemia Working Party of the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol 2006, 24:3959-3966.
11. Boccadoro M., Palumbo A., Bringhen S., Merletti F., Ciccone G., Richiardi L., et al. Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. Haematologica 2002, 87:846-850.
12. Kumar S., Dispenzieri A., Lacy M.Q., Hayman S.R., Buadi F.K., Gastineau D.A., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
13. Popat U., Saliba R., Thandi R., Hosing C., Qazilbash M., Anderlini P., et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009, 15:718-723.
14. Tournilhac O., Cazin B., Lepretre S., Divine M., Maloum K., Delmer A., et al. Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia. Blood 2004, 103:363-365.
15. Laszlo D., Galieni P., Raspadori D., Tozzi M., Lauria F., Martinelli G. Fludarabine combination regimen severely affected peripheral blood stem cell mobilization. Acta Haematol 2004, 111:228-229.
16. Nickenig C., Dreyling M., Hoster E., Ludwig W.D., Dorken B., Freund M., et al. Initial chemotherapy with mitoxantrone, chlorambucil, prednisone impairs the collection of stem cells in patients with indolent lymphomas-results of a randomized comparison by the German Low-Grade Lymphoma Study Group. Ann Oncol 2007, 18:136-142.
17. Clark R.E., Brammer C.G. Previous treatment predicts the efficiency of blood progenitor cell mobilisation: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998, 22:859-863.
18. Keane C., Gibbs S., Seymour J.F., Mills A.K., Grimmett K., Van Kuilenberg R., et al. The hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematol Oncol 2006, 24:159-163.
19. Olivieri A., Brunori M., Capelli D., Montanari M., Massidda D., Gini G., et al. Salvage therapy with an outpatient DHAP schedule followed by PBSC transplantation in 79 lymphoma patients: an intention to mobilize and transplant analysis. Eur J Haematol 2004, 72:10-17.
20. Hosing C., Saliba R.M., Ahlawat S., Korbling M., Kebriaei P., Alousi A., et al. Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma. Am J Hematol 2009, 84:335-337.
21. Kuittinen T., Nousiainen T., Halonen P., Mahlamaki E., Jantunen E. Prediction of mobilisation failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004, 33:907-912.
22. Putkonen M., Rauhala A., Pelliniemi T.T., Remes K. Sepsis, low platelet nadir at mobilization and previous IFN use predict stem cell mobilization failure in patients with multiple myeloma. Cytotherapy 2007, 9:548-554.
23. Ozkurt Z.N., Yegin Z.A., Suyani E., Aki S.Z., Acar K., Yagci M., et al. Factors affecting stem cell mobilization for autologous hematopoietic stem cell transplantation. J Clin Apher 2010, 25:280-286.
24. Corso A., Varettoni M., Mangiacavalli S., Zappasodi P., Klersy C., Rusconi C., et al. Bone marrow CD34+ cell count is predictive for adequate peripheral progenitor cell collection. Leuk Res 2005, 29:159-163.
25. Shimizu N., Asai T., Hashimoto S., Narita M., Kobayashi M., Ito M., et al. Mobilization factors of peripheral blood stem cells in healthy donors. Ther Apher 2002, 6:413-418.
26. Fadini G.P., Pucci L., Vanacore R., Baesso I., Penno G., Balbarini A., et al. Glucose tolerance is negatively associated with circulating progenitor cell levels. Diabetologia 2007, 50:2156-2163.
27. Fadini G.P., Boscaro E., de Kreutzenberg S., Agostini C., Seeger F., Dimmeler S., et al. Time course and mechanisms of circulating progenitor cell reduction in the natural history of type 2 diabetes. Diabetes Care 2010, 33:1097-1102.
28. Ferraro F., Lymperi S., Mendez-Ferrer S., Saez B., Spencer J.A., Yeap B.Y., et al. Diabetes impairs hematopoietic stem cell mobilization by altering niche function. Sci Transl Med 2011, 3:104ra1.
29. Li L., Xie T. Stem cell niche: structure and function. Annu Rev Cell Dev Biol 2005, 21:605-631.
30. Lin H. The stem-cell niche theory: lessons from flies. Nat Rev Genet 2002, 3:931-940.
31. Mendez-Ferrer S., Michurina T.V., Ferraro F., Mazloom A.R., Macarthur B.D., Lira S.A., et al. Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature 2010, 466:829-834.
32. Spiegel A., Shivtiel S., Kalinkovich A., Ludin A., Netzer N., Goichberg P., et al. Catecholaminergic neurotransmitters regulate migration and repopulation of immature human CD34+ cells through Wnt signaling. Nat Immunol 2007, 8:1123-1131.
33. Heissig B., Hattori K., Dias S., Friedrich M., Ferris B., Hackett N.R., et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. Cell 2002, 109:625-637.
34. Levesque J.P., Takamatsu Y., Nilsson S.K., Haylock D.N., Simmons P.J. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001, 98:1289-1297.
35. Levesque J.P., Hendy J., Takamatsu Y., Simmons P.J., Bendall L.J. Disruption of the CXCR4/CXCL12 chemotactic interaction during hematopoietic stem cell mobilization induced by GCSF or cyclophosphamide. J Clin Investig 2003, 111:187-196.
36. Broxmeyer H.E. Chemokines in hematopoiesis. Curr Opin Hematol 2008, 15:49-58.
37. Sugiyama T., Kohara H., Noda M., Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006, 25:977-988.
38. Ehninger A., Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med 2011, 208:421-428.
39. Arai F., Hirao A., Ohmura M., Sato H., Matsuoka S., Takubo K., et al. Tie2/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche. Cell 2004, 118:149-161.
40. Qian H., Buza-Vidas N., Hyland C.D., Jensen C.T., Antonchuk J., Mansson R., et al. Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 2007, 1:671-684.
41. Chow A., Lucas D., Hidalgo A., Mendez-Ferrer S., Hashimoto D., Scheiermann C., et al. Bone marrow CD169+ macrophages promote the retention of hematopoietic stem and progenitor cells in the mesenchymal stem cell niche. J Exp Med 2011, 208:261-271.
42. Christopher M.J., Rao M., Liu F., Woloszynek J.R., Link D.C. Expression of the G-CSF receptor in monocytic cells is sufficient to mediate hematopoietic progenitor mobilization by G-CSF in mice. J Exp Med 2011, 208:251-260.
43. Winkler I.G., Sims N.A., Pettit A.R., Barbier V., Nowlan B., Helwani F., et al. Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs. Blood 2010, 116:4815-4828.
44. Wright D.E., Wagers A.J., Gulati A.P., Johnson F.L., Weissman I.L. Physiological migration of hematopoietic stem and progenitor cells. Science 2001, 294:1933-1936.
45. Kollet O., Dar A., Lapidot T. The multiple roles of osteoclasts in host defense: bone remodeling and hematopoietic stem cell mobilization. Annu Rev Immunol 2007, 25:51-69.
46. Petit I., Szyper-Kravitz M., Nagler A., Lahav M., Peled A., Habler L., et al. G-CSF induces stem cell mobilization by decreasing bone marrow SDF-1 and up-regulating CXCR4. Nat Immunol 2002, 3:687-694.
47. Levesque J.P., Hendy J., Takamatsu Y., Williams B., Winkler I.G., Simmons P.J. Mobilization by either cyclophosphamide or granulocyte colony-stimulating factor transforms the bone marrow into a highly proteolytic environment. Exp Hematol 2002, 30:440-449.
48. Pelus L.M., Bian H., King A.G., Fukuda S. Neutrophil-derived MMP-9 mediates synergistic mobilization of hematopoietic stem and progenitor cells by the combination of G-CSF and the chemokines GRObeta/CXCL2 and GRObetaT/CXCL2delta4. Blood 2004, 103:110-119.
49. Levesque J.P., Liu F., Simmons P.J., Betsuyaku T., Senior R.M., Pham C., et al. Characterization of hematopoietic progenitor mobilization in protease-deficient mice. Blood 2004, 104:65-72.
50. Levesque J.P., Hendy J., Winkler I.G., Takamatsu Y., Simmons P.J. Granulocyte colony-stimulating factor induces the release in the bone marrow of proteases that cleave c-KIT receptor (CD117) from the surface of hematopoietic progenitor cells. Exp Hematol 2003, 31:109-117.
51. Semerad C.L., Christopher M.J., Liu F., Short B., Simmons P.J., Winkler I., et al. G-CSF potently inhibits osteoblast activity and CXCL12 mRNA expression in the bone marrow. Blood 2005, 106:3020-3027.
52. Nademanee A., Sniecinski I., Schmidt G.M., Dagis A.C., O'Donnell M.R., Snyder D.S., et al. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells. J Clin Oncol 1994, 12:2176-2186.
53. Schmitz N., Linch D.C., Dreger P., Goldstone A.H., Boogaerts M.A., Ferrant A., et al. Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet 1996, 347:353-357.
54. Bensinger W.I., Martin P.J., Storer B., Clift R., Forman S.J., Negrin R., et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 2001, 344:175-181.
55. Blaise D., Kuentz M., Fortanier C., Bourhis J.H., Milpied N., Sutton L., et al. Randomized trial of bone marrow versus lenograstim-primed blood cell allogeneic transplantation in patients with early-stage leukemia: a report from the Societe Francaise de Greffe de Moelle. J Clin Oncol 2000, 18:537-546.
56. Couban S., Simpson D.R., Barnett M.J., Bredeson C., Hubesch L., Howson-Jan K., et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood 2002, 100:1525-1531.
57. Schmitz N., Beksac M., Hasenclever D., Bacigalupo A., Ruutu T., Nagler A., et al. Transplantation of mobilized peripheral blood cells to HLA-identical siblings with standard-risk leukemia. Blood 2002, 100:761-767.
58. Lane T.A., Law P., Maruyama M., Young D., Burgess J., Mullen M., et al. Harvesting and enrichment of hematopoietic progenitor cells mobilized into the peripheral blood of normal donors by granulocyte-macrophage colony-stimulating factor (GM-CSF) or G-CSF: potential role in allogeneic marrow transplantation. Blood 1995, 85:275-282.
59. Gazitt Y., Shaughnessy P., Liu Q. Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001, 10:167-176.
60. Gazitt Y., Shaughnessy P., Devore P. Mobilization of dendritic cells and NK cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001, 10:177-186.
61. Devine S.M., Brown R.A., Mathews V., Trinkaus K., Khoury H., Adkins D., et al. Reduced risk of acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone. Bone Marrow Transplant 2005, 36:531-538.
62. Nie Y., Han Y.C., Zou Y.R. CXCR4 is required for the quiescence of primitive hematopoietic cells. J Exp Med 2008, 205:777-783.
63. Tzeng Y.S., Li H., Kang Y.L., Chen W.C., Cheng W.C., Lai D.M. Loss of Cxcl12/Sdf-1 in adult mice decreases the quiescent state of hematopoietic stem/progenitor cells and alters the pattern of hematopoietic regeneration after myelosuppression. Blood 2011, 117:429-439.
64. Devine S.M., Flomenberg N., Vesole D.H., Liesveld J., Weisdorf D., Badel K., et al. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol Off J Am Soc Clin Oncol 2004, 22:1095-1102.
65. Flomenberg N., Devine S.M., Dipersio J.F., Liesveld J.L., McCarty J.M., Rowley S.D., et al. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood 2005, 106:1867-1874.
66. Cashen A., Lopez S., Gao F., Calandra G., MacFarland R., Badel K., et al. A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. Biology of blood and marrow transplantation. J. Am Soc Blood Marrow Transplant 2008, 14:1253-1261.
67. Fowler C.J., Dunn A., Hayes-Lattin B., Hansen K., Hansen L., Lanier K., et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009, 43:909-917.
68. Stiff P., Micallef I., McCarthy P., Magalhaes-Silverman M., Weisdorf D., Territo M., et al. Treatment with plerixafor in non-Hodgkin's lymphoma and multiple myeloma patients to increase the number of peripheral blood stem cells when given a mobilizing regimen of G-CSF: implications for the heavily pretreated patient. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2009, 15:249-256.
69. Calandra G., McCarty J., McGuirk J., Tricot G., Crocker S.A., Badel K., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
70. DiPersio J.F., Micallef I.N., Stiff P.J., Bolwell B.J., Maziarz R.T., Jacobsen E., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
71. DiPersio J.F., Stadtmauer E.A., Nademanee A., Micallef I.N., Stiff P.J., Kaufman J.L., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
72. Devine S.M., Vij R., Rettig M., Todt L., McGlauchlen K., Fisher N., et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008, 112:990-998.
73. Schroeder M.A., Lopez S., Rettig M.P., Trinkaus K., Westervelt P., DiPersio J.F. High dose sargramostim (GM-CSF) combined with IV plerixafor for the mobilization of peripheral blood stem cells (PBSC) from normal HLA-matched allogeneic sibling donors results in hypercoagulability. ASH Annu Meet Abstr 2012, 120:4095.
74. Liles W.C., Broxmeyer H.E., Rodger E., Wood B., Hubel K., Cooper S., et al. Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist. Blood 2003, 102:2728-2730.
75. Hubel K., Liles W.C., Broxmeyer H.E., Rodger E., Wood B., Cooper S., et al. Leukocytosis and mobilization of CD34+ hematopoietic progenitor cells by AMD3100, a CXCR4 antagonist. Support Cancer Ther 2004, 1:165-172.
76. Liles W.C., Rodger E., Broxmeyer H.E., Dehner C., Badel K., Calandra G., et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
77. Stewart D.A., Smith C., MacFarland R., Calandra G. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. Biology of blood and marrow transplantation. J. Am. Soc. Blood Marrow Transpl 2009, 15:39-46.
78. Lefrere F., Mauge L., Rea D., Ribeil J.A., Dal Cortivo L., Brignier A.C., et al. A specific time course for mobilization of peripheral blood CD34+ cells after plerixafor injection in very poor mobilizer patients: impact on the timing of the apheresis procedure. Transfusion 2013, 53:564-569.
79. Vishnu P., Roy V., Paulsen A., Zubair A.C. Efficacy and cost-benefit analysis of risk-adaptive use of plerixafor for autologous hematopoietic progenitor cell mobilization. Transfusion 2012, 52:55-62.
80. Li J., Hamilton E., Vaughn L., Graiser M., Renfroe H., Lechowicz M.J., et al. Effectiveness and cost analysis of "just-in-time" salvage plerixafor administration in autologous transplant patients with poor stem cell mobilization kinetics. Transfusion 2011, 51:2175-2182.
81. Costa L.J., Alexander E.T., Hogan K.R., Schaub C., Fouts T.V., Stuart R.K. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011, 46:64-69.
82. Smith V.R., Popat U., Ciurea S., Nieto Y., Anderlini P., Rondon G., et al. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 2013, 88:754-757.
83. Farina L., Spina F., Guidetti A., Longoni P., Ravagnani F., Dodero A., et al. Peripheral blood CD34+ cell monitoring after cyclophosphamide and granulocyte-colony-stimulating factor: an algorithm for the pre-emptive use of plerixafor. Leuk Lymphoma 2013 Jun 14, [Electronic publication ahead of print] [PubMed PMID: 23656194], http://dx.doi.org/10.31091.
84. Maziarz R.T., Nademanee A.P., Micallef I.N., Stiff P.J., Calandra G., Angell J., et al. Plerixafor plus granulocyte colony-stimulating factor improves the mobilization of hematopoietic stem cells in patients with non-Hodgkin lymphoma and low circulating peripheral blood CD34+ cells. Biol Blood Marrow Transplant 2013, 19:670-675.
85. Ding L., Saunders T.L., Enikolopov G., Morrison S.J. Endothelial and perivascular cells maintain haematopoietic stem cells. Nature 2012, 481:457-462.
86. Broudy V.C. Stem cell factor and hematopoiesis. Blood 1997, 90:1345-1364.
87. Levesque J.P., Leavesley D.I., Niutta S., Vadas M., Simmons P.J. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins. J Exp Med 1995, 181:1805-1815.
88. Dahlen D.D., Lin N.L., Liu Y.C., Broudy V.C. Soluble kit receptor blocks stem cell factor bioactivity in vitro. Leuk Res 2001, 25:413-421.
89. Herbert K.E., Morgan S., Prince H.M., Westerman D.A., Wolf M.M., Carney D.A., et al. Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator. Leukemia 2009, 23:305-312.
90. To L.B., Bashford J., Durrant S., MacMillan J., Schwarer A.P., Prince H.M., et al. Successful mobilization of peripheral blood stem cells after addition of ancestim (stem cell factor) in patients who had failed a prior mobilization with filgrastim (granulocyte colony-stimulating factor) alone or with chemotherapy plus filgrastim. Bone Marrow Transplant 2003, 31:371-378.
91. Prosper F., Sola C., Hornedo J., Arbona C., Menendez P., Orfao A., et al. Mobilization of peripheral blood progenitor cells with a combination of cyclophosphamide, r-metHuSCF and filgrastim in patients with breast cancer previously treated with chemotherapy. Leukemia 2003, 17:437-441.
92. Stiff P., Gingrich R., Luger S., Wyres M.R., Brown R.A., LeMaistre C.F., et al. A randomized phase 2 study of PBPC mobilization by stem cell factor and filgrastim in heavily pretreated patients with Hodgkin's disease or non-Hodgkin's lymphoma. Bone Marrow Transplant 2000, 26:471-481.
93. Moskowitz C.H., Stiff P., Gordon M.S., McNiece I., Ho A.D., Costa J.J., et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients-results of a phase I/II trial. Blood 1997, 89:3136-3147.
94. Basser R.L., To L.B., Begley C.G., Maher D., Juttner C., Cebon J., et al. Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor. J Clin Oncol Off J Am Soc Clin Oncol 1998, 16:1899-1908.
95. Facon T., Harousseau J.L., Maloisel F., Attal M., Odriozola J., Alegre A., et al. Stem cell factor in combination with filgrastim after chemotherapy improves peripheral blood progenitor cell yield and reduces apheresis requirements in multiple myeloma patients: a randomized, controlled trial. Blood 1999, 94:1218-1225.
96. Shpall E.J., Wheeler C.A., Turner S.A., Yanovich S., Brown R.A., Pecora A.L., et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999, 93:2491-2501.
97. Glaspy J.A., Shpall E.J., LeMaistre C.F., Briddell R.A., Menchaca D.M., Turner S.A., et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood 1997, 90:2939-2951.
98. Lapierre V., Rossi J.F., Heshmati F., Azar N., Vekhof A., Makowski C., et al. Ancestim (r-metHuSCF) plus filgrastim and/or chemotherapy for mobilization of blood progenitors in 513 poorly mobilizing cancer patients: the French compassionate experience. Bone Marrow Transplant 2011, 46:936-942.
99. Fitoussi O., Perreau V., Boiron J.M., Bouzigon E., Cony-Makhoul P., Pigneux A., et al. A comparison of toxicity following two different doses of cyclophosphamide for mobilization of peripheral blood progenitor cells in 116 multiple myeloma patients. Bone Marrow Transplant 2001, 27:837-842.
100. Goldschmidt H., Hegenbart U., Wallmeier M., Hohaus S., Haas R. Factors influencing collection of peripheral blood progenitor cells following high-dose cyclophosphamide and granulocyte colony-stimulating factor in patients with multiple myeloma. Br J Haematol 1997, 98:736-744.
101. Jantunen E., Putkonen M., Nousiainen T., Pelliniemi T.T., Mahlamaki E., Remes K. Low-dose or intermediate-dose cyclophosphamide plus granulocyte colony-stimulating factor for progenitor cell mobilisation in patients with multiple myeloma. Bone Marrow Transplant 2003, 31:347-351.
102. Hiwase D.K., Bollard G., Hiwase S., Bailey M., Muirhead J., Schwarer A.P. Intermediate-dose CY and G-CSF more efficiently mobilize adequate numbers of PBSC for tandem autologous PBSC transplantation compared with low-dose CY in patients with multiple myeloma. Cytotherapy 2007, 9:539-547.
103. Hamadani M., Kochuparambil S.T., Osman S., Cumpston A., Leadmon S., Bunner P., et al. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies. Biol Blood Marrow Transplant 2012, 18:1128-1135.
104. Pavone V., Gaudio F., Guarini A., Perrone T., Zonno A., Curci P., et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002, 29:285-290.
105. Lee J.L., Kim S., Kim S.W., Kim E.K., Kim S.B., Kang Y.K., et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005, 35:449-454.
106. Akhtar S., Tbakhi A., Humaidan H., El Weshi A., Rahal M., Maghfoor I. ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 2006, 37:277-282.
107. Watts M.J., Ings S.J., Leverett D., MacMillan A., Devereux S., Goldstone A.H., et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5gm(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000, 82:278-282.
108. Mollee P., Pereira D., Nagy T., Song K., Saragosa R., Keating A., et al. Cyclophosphamide, etoposide and G-CSF to mobilize peripheral blood stem cells for autologous stem cell transplantation in patients with lymphoma. Bone Marrow Transplant 2002, 30:273-278.
109. Pocali B., De Simone M., Annunziata M., Palmieri S., D'Amico M.R., Copia C., et al. Ifosfamide, epirubicin and etoposide (IEV) regimen as salvage and mobilization therapy for refractory or early relapsing patients with aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2004, 45:1605-1609.
110. Rettig M.P., Ansstas G., DiPersio J.F. Mobilization of hematopoietic stem and progenitor cells using inhibitors of CXCR4 and VLA-4. Leukemia 2012, 26:34-53.
111. Schmitt S., Weinhold N., Dembowsky K., Neben K., Witzens-Harig M., Braun M., et al. First results of a Phase-II study with the new CXCR4 antagonist POL6326 to mobilize hematopoietic stem cells (HSC) in multiple myeloma (MM). ASH Annu Meet Abstr 2010, 116:824.
112. Abraham M., Biyder K., Begin M., Wald H., Weiss I.D., Galun E., et al. Enhanced unique pattern of hematopoietic cell mobilization induced by the CXCR4 antagonist 4F-benzoyl-TN14003. Stem Cells 2007, 25:2158-2166.
113. Nagler A., Shimoni A., Avivi I., Rowe J.M., Beider K., Hardan I., et al. BKT140 is a novel CXCR4 antagonist with stem cell mobilization and antimyeloma effects: an open-label first human trial in patients with multiple myeloma undergoing stem cell mobilization for autologous transplantation. ASH Annu Meet Abstr 2010, 116:2260.
114. Chung D.T., Chang L.-W., Huang Y.-H., Tsai C.-Y., Hsu C.-H., King C.-H.R., et al. TG-0054, a novel and potent stem cell mobilizer, displays excellent PK/PD and safety profile in Phase I trial. ASH Annu Meet Abstr 2009, 114:866.
115. Scheller M., Schwoebel F., Vossmeyer D., Leutz A. Rapid and efficient mobilization of murine hematopoietic stem and progenitor cells with Nox-A12, a new Spiegelmers(R)-based CXCR4/SDF-1(CXCL12) antagonist. ASH Annu Meet Abstr 2011, 118:2995.
116. Gobbi M., Caligaris-Cappio F., Montillo M., Vauleon S., Zollner S., Dummler T., et al. Phase IIa study of the anti-CXCL12/SDF-1 spiegelmer(R) Nox-A12 alone and combined with bendamustine/rituximab in patients with relapsed chronic lymphocytic leukemia (CLL). ASH Annu Meet Abstr 2012, 120:4593.
117. Zboralski D., Hoellenriegel J., Maasch C., Kruschinski A., Burger J.A. Mode of action of the SDF-1/CXCL12 inhibiting Spiegelmer(R) Nox-A12 and its impact on chronic lymphocytic leukemia (CLL) cell motility and chemosensitization. ASH Annu Meet Abstr 2012, 120:318.
118. Hoellenriegel J., Zboralski D., Estrov Z., Wierda W.G., Keating M., Kruschinski A., et al. The Spiegelmer Nox-A12, a novel SDF-1 (CXCL12) inhibitor, and its effects on chronic lymphocytic leukemia (CLL) cell migration. ASH Annu Meet Abstr 2011, 118:3878.
119. Roccaro A.M., Sacco A., Ungari M., Maiso P., Manier S., Quang P., et al. In vivo targeting of stromal-derived factor-1 as a strategy to prevent myeloma cell dissemination to distant bone marrow niches. ASH Annu Meet Abstr 2012, 120:440.
120. Hanel P., Andreani P., Graler M.H. Erythrocytes store and release sphingosine 1-phosphate in blood. FASEB J 2007, 21:1202-1209.
121. Ohkawa R., Nakamura K., Okubo S., Hosogaya S., Ozaki Y., Tozuka M., et al. Plasma sphingosine-1-phosphate measurement in healthy subjects: close correlation with red blood cell parameters. Ann Clin Biochem 2008, 45:356-363.
122. Sanchez T., Hla T. Structural and functional characteristics of S1P receptors. J Cell Biochem 2004, 92:913-922.
123. Peest U., Sensken S.C., Andreani P., Hanel P., Van Veldhoven P.P., Graler M.H. S1P-lyase independent clearance of extracellular sphingosine 1-phosphate after dephosphorylation and cellular uptake. J Cell Biochem 2008, 104:756-772.
124. Schwab S.R., Pereira J.P., Matloubian M., Xu Y., Huang Y., Cyster J.G. Lymphocyte sequestration through S1P lyase inhibition and disruption of S1P gradients. Science 2005, 309:1735-1739.
125. Massberg S., Schaerli P., Knezevic-Maramica I., Kollnberger M., Tubo N., Moseman E.A., et al. Immunosurveillance by hematopoietic progenitor cells trafficking through blood, lymph, and peripheral tissues. Cell 2007, 131:994-1008.
126. Ratajczak M.Z., Lee H., Wysoczynski M., Wan W., Marlicz W., Laughlin M.J., et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia 2010, 24:976-985.
127. Lee H.M., Wu W., Wysoczynski M., Liu R., Zuba-Surma E.K., Kucia M., et al. Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes. Leukemia 2009, 23:2052-2062.
128. Mierzejewska K., Kucia M., Ratajczak J., Ratajczak M.Z. Novel evidence that hematopoietic stem/progenitor cells (HSPCs) are mobilized during hemolysis in an erythrocyte lysis-derived, sphingosine-1-phosphate (S1P)-dependent manner-the crucial involvement of complement cascade (CC) activation and attenuation of CXCR4 retention signaling. ASH Annu Meet Abstr. 2012, 120:3189.
129. Juarez J.G., Harun N., Thien M., Welschinger R., Baraz R., Pena A.D., et al. Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice. Blood 2012, 119:707-716.
130. Hynes R.O. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992, 69:11-25.
131. Springer T.A. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994, 76:301-314.
132. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J Cell Sci 2006, 119:3901-3903.
133. Elices M.J., Osborn L., Takada Y., Crouse C., Luhowskyj S., Hemler M.E., et al. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990, 60:577-584.
134. Papayannopoulou T., Nakamoto B. Peripheralization of hemopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci U S A 1993, 90:9374-9378.
135. Vermeulen M., Le Pesteur F., Gagnerault M.C., Mary J.Y., Sainteny F., Lepault F. Role of adhesion molecules in the homing and mobilization of murine hematopoietic stem and progenitor cells. Blood 1998, 92:894-900.
136. Jing D., Oelschlaegel U., Ordemann R., Holig K., Ehninger G., Reichmann H., et al. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant 2010, 45:1489-1496.
137. Zohren F., Toutzaris D., Klarner V., Hartung H.P., Kieseier B., Haas R. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008, 111:3893-3895.
138. Bonig H., Wundes A., Chang K.H., Lucas S., Papayannopoulou T. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008, 111:3439-3441.
139. Bonig H., Watts K.L., Chang K.H., Kiem H.P., Papayannopoulou T. Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. Stem Cells 2009, 27:836-837.
140. Ramirez P., Rettig M.P., Uy G.L., Deych E., Holt M.S., Ritchey J.K., et al. BIO5192, a small molecule inhibitor of VLA-4, mobilizes hematopoietic stem and progenitor cells. Blood 2009, 114:1340-1343.
141. Brunner S., Theiss H.D., Murr A., Negele T., Franz W.M. Primary hyperparathyroidism is associated with increased circulating bone marrow-derived progenitor cells. Am J Physiol Endocrinol Metab 2007, 293:E1670-E1675.
142. Brunner S., Zaruba M.M., Huber B., David R., Vallaster M., Assmann G., et al. Parathyroid hormone effectively induces mobilization of progenitor cells without depletion of bone marrow. Exp Hematol 2008, 36:1157-1166.
143. Ballen K.K., Shpall E.J., Avigan D., Yeap B.Y., Fisher D.C., McDermott K., et al. Phase I trial of parathyroid hormone to facilitate stem cell mobilization. Biology of blood and marrow transplantation. J Am Soc Blood Marrow Transplant 2007, 13:838-843.
144. Ghobadi A., Holt M., Ritchey J., DiPersio J.F. The effect of bortezomib (B) alone or in combination with other agents for stem cell mobilization in mice. ASH Annu Meet Abstr 2012, 120:583.
145. Niesvizky R., Mark T.M., Ward M., Jayabalan D.S., Pearse R.N., Manco M., et al. Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization. Clin Cancer Res 2013, 19:1534-1546.
146. Haskill S., Peace A., Morris J., Sporn S.A., Anisowicz A., Lee S.W., et al. Identification of three related human GRO genes encoding cytokine functions. Proc Natl Acad Sci U S A 1990, 87:7732-7736.
147. King A.G., Horowitz D., Dillon S.B., Levin R., Farese A.M., MacVittie T.J., et al. Rapid mobilization of murine hematopoietic stem cells with enhanced engraftment properties and evaluation of hematopoietic progenitor cell mobilization in rhesus monkeys by a single injection of SB-251353, a specific truncated form of the human CXC chemokine GRObeta. Blood 2001, 97:1534-1542.
148. Fukuda S., Bian H., King A.G., Pelus L.M. The chemokine GRObeta mobilizes early hematopoietic stem cells characterized by enhanced homing and engraftment. Blood 2007, 110:860-869.
149. Winkler I.G., Barbier V., Wadley R., Zannettino A.C., Williams S., Levesque J.P. Positioning of bone marrow hematopoietic and stromal cells relative to blood flow in vivo: serially reconstituting hematopoietic stem cells reside in distinct nonperfused niches. Blood 2010, 116:375-385.
150. Parmar K., Mauch P., Vergilio J.A., Sackstein R., Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007, 104:5431-5436.
151. Wang G.L., Semenza G.L. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995, 270:1230-1237.
152. Bruick R.K., McKnight S.L. A conserved family of prolyl-4-hydroxylases that modify HIF. Science 2001, 294:1337-1340.
153. 2-regulated prolyl hydroxylation. Science 2001, 292:468-472.
154. Cramer T., Yamanishi Y., Clausen B.E., Forster I., Pawlinski R., Mackman N., et al. HIF-1alpha is essential for myeloid cell-mediated inflammation. Cell 2003, 112:645-657.
155. Ceradini D.J., Kulkarni A.R., Callaghan M.J., Tepper O.M., Bastidas N., Kleinman M.E., et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004, 10:858-864.
156. Levesque J.P., Winkler I.G., Hendy J., Williams B., Helwani F., Barbier V., et al. Hematopoietic progenitor cell mobilization results in hypoxia with increased hypoxia-inducible transcription factor-1 alpha and vascular endothelial growth factor A in bone marrow. Stem Cells 2007, 25:1954-1965.
157. Forsythe J.A., Jiang B.H., Iyer N.V., Agani F., Leung S.W., Koos R.D., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
158. 2 homeostasis by hypoxia-inducible factor 1. Annu Rev Cell Dev Biol 1999, 15:551-578.
159. Forristal C.E., Nowlan B., Barbier V., Winkler I.G., Walkinshaw G., Levesque J.-P. FG-4497, a pharmacological stabilizer of HIF-1{alpha} protein, synergistically enhances hematopoietic stem cells (HSC) mobilization in response to G-CSF and plerixafor. ASH Annu Meet Abstr 2012, 120:216.